ArticleMaterials today. Bio2025
Neodymium-doped mesoporous silica nanoparticles promote bone regeneration via autophagy-mediated macrophage immunomodulation.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Smart Mesoporous Silica Nanoparticle-Based Drug Delivery Systems: Recent Advances in Biomedical Applications, Wound Healing and Therapeutic Perspectives.Pharmaceutics · 2026Review
- [Bioactive substances delivery for bone repair via nanocomposites: advantages, mechanisms, and emerging trends].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
- Biomaterials targeting senescent cells for bone regeneration: State-of-the-art and future perspectives.Bioactive materials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rare earth nanomaterials, especially those incorporating neodymium, hold great potential for bone regeneration, but their clinical application is limited by insufficient understanding of immunomodulatory effects and potential toxicity concerns. To address this, we developed neodymium-doped mesoporous silica nanoparticles (NDMSN) to modulate macrophage autophagy and polarization. NDMSN exhibited uniform dispersion with an average size of 103 nm. NDMSN displayed low cytotoxicity in M0 macrophages and effectively suppressed pro-inflammatory responses in M1 macrophages. This was evidenced by the inhibition of pro-inflammatory markers (IL-6, IL-1β, and iNOS) and the promotion of anti-inflammatory markers (IL-4, IL-10, and CD206). Autophagy activation was confirmed by upregulated expression of P62, LC3A, BECLIN1, and ATG7, and the anti-inflammatory effects were attenuated upon autophagy inhibition with 3-methyladenine, highlighting autophagy's essential role. Conditioned medium from NDMSN-treated M1 macrophages exhibited pro-angiogenic activity in human umbilical vein endothelial cells by enhancing tube formation and elevating angiogenic gene expression, while showing pro-osteogenic potential in mouse bone marrow mesenchymal stromal cells. In vivo, NDMSN mitigated LPS-induced bone destruction in a mouse calvarial osteolysis model and suppressed osteoclast differentiation. Its osteogenic capacity was further validated in a zebrafish calvarial defect model. These findings demonstrate that NDMSN is a promising immunomodulatory and osteogenic nanomaterial, offering a novel therapeutic strategy for bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.